A Multicenter, Open-label, Phase 3b Efficacy and Safety Study of Benralizumab 30 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Patients with Severe Eosinophilic Asthma on High-Dose Inhaled Corticosteroid plus Long-acting ?2 Ag

Project: Other project

StatusActive
Effective start/end date10/19/1810/18/20

Funding

  • AstraZeneca LP: $6,311.54